Analytical Data
-
Gene name
GNAZ
- Application
-
Alternative Names
GN-AZ; Guanine Nucleotide Binding Protein Alpha Z; G(x) alpha chain
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P19086
-
Expression Region
Gly2~Val219
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GNAZ, or Guanine nucleotide-binding protein, alpha Z, is a member of the G protein family that plays a pivotal role in signal transduction pathways, particularly in mediating the actions of various receptors, including G protein-coupled receptors (GPCRs). Research on GNAZ has increasingly gained attention due to its involvement in critical physiological processes such as neurotransmission, hormone signaling, and sensory perception. Unlike other G protein subtypes, GNAZ primarily functions in specific tissues, particularly in the brain and immune system, influencing cellular responses through various downstream effectors. The study of GNAZ-recombinant proteins has significant implications for understanding the molecular mechanisms underpinning these signaling pathways. Furthermore, GNAZ has been implicated in certain pathological conditions, including neurological disorders and cancer, making it a target for therapeutic interventions. The development of GNAZ-recombinant proteins allows researchers to dissect its functional properties, investigate its interactions with different ligands and receptors, and explore its potential as a biomarker or therapeutic target. By utilizing advanced techniques such as gene cloning, affinity purification, and functional assays, researchers aim to elucidate the intricate role of GNAZ in cellular signaling and its broader implications for health and disease, contributing to the growing body of knowledge in molecular biology and pharmacology.
